Floatz logo

Polyiclc

Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Mayo ClinicPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Epirubicin
Mayo Clinic
Phase 1/2CCC
FLUTICASONE
Mayo Clinic
Phase 1/2CCC
Cyclophosphamide
Mayo Clinic
Phase 1/2CCC
FILGRASTIM
Mayo Clinic
Phase 1/2CCC
Sargramostim
Mayo Clinic
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →